Drug Search Results
More Filters [+]

Lomefloxacin

Alternative Names: lomefloxacin, maxaquin
Latest Update: 2021-04-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Bangladesh | Brazil | Chile | Colombia | Dominican Republic | Egypt | France | Germany | India | Ireland | Italy | Jordan | Korea | Mexico | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Singapore | South Africa | Sri Lanka | Taiwan | Turkey | Ukraine | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Julio Ramirez
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lomefloxacin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Osteomyelitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PRESTO:Osteo

P1

Terminated

Osteomyelitis

2018-11-07

Recent News Events

Date

Type

Title